Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 19/20 | 0.89 |
| ▸ | MAPT | P10636 | 19/20 | 0.89 |
| ▸ | TP53 | P04637 | 9/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077271 | 0.94 | GAA (1.00) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2250773 | 0.81 | GAA (0.73) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2250222 | 0.81 | GAA (1.00) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2251935 | 0.79 | MAPT (0.74) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2254381 | 0.79 | GAA (0.70) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2257110 | 0.79 | GAA (0.71) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2253480 | 0.78 | GAA (0.69) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2255410 | 0.78 | GAA (0.68) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2251728 | 0.78 | MAPT (0.68) | GAAMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL2254407 | 0.77 | MAPT (0.67) | GAAMAPTTP53KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065251-B2 | PAK1 inhibitors and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-07-20 | — | — | US | disclosed |
| US-11065251-B2 | PAK1 inhibitors and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| WO-2017192228-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065251-B2 | PAK1 inhibitors and uses thereof | PAK1, CDC42, CDC42BPG | GAA 3778/4885MAPT 3472/4885TP53 192/4885 |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | PAK1, CDC42, CDC42BPG | GAA 3778/4885MAPT 3472/4885TP53 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.